GlassScriptPhysician profile
Andrew W Dake
NPI 1043507965
$18,753.71
in general payments reported to CMS, 2019-2025
55 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,937 · 2020: $2,035 · 2021: $2,322 · 2022: $3,239 · 2023: $2,869 · 2024: $2,667 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,219.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,645.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,918.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,242.86 | 2019-2024 | |
| Dexcom, INC. | $1,218.94 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $995.69 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $967.73 | 2019-2025 | Afrezza |
| Corcept Therapeutics | $823.30 | 2019-2025 | Korlym |
| Merck Sharp & Dohme LLC | $751.68 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $632.04 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $609.18 | 2019-2023 | Lokelma, Farxiga |
| Insulet Corporation | $576.14 | 2019-2025 | Omnipod |
| Amgen INC. | $555.20 | 2019-2025 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $550.27 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $516.78 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.41 | 2019-2024 | Jardiance |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $401.66 | 2019-2023 | |
| Medtronic, INC. | $334.74 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Ultragenyx Pharmaceutical INC. | $326.69 | 2021-2025 | Crysvita |
| Radius Health, INC. | $260.54 | 2019-2025 | Tymlos |
| Cequr Corporation | $225.56 | 2024-2025 | Cequr Simplicity |
| Pfizer INC. | $210.50 | 2019-2025 | |
| Antares Pharma, INC. | $184.92 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.49 | 2019-2022 | |
| Lifescan, INC. | $153.76 | 2019-2022 | |
| Zealand Pharma US, INC. | $153.26 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $148.19 | 2024-2025 | Crenessity |
| Horizon Therapeutics Plc | $130.62 | 2021-2023 | Tepezza |
| Beta Bionics, INC. | $124.99 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $105.28 | 2025 | Yorvipath |
| Ibsa Pharma INC. | $103.25 | 2020-2025 | Tirosint, Licart, Flector |
| Janssen Pharmaceuticals, INC | $97.12 | 2019 | |
| Medtronic Minimed, INC. | $95.40 | 2019-2020 | |
| Amphastar Pharmaceuticals, INC. | $91.47 | 2024-2025 | |
| Abbvie INC. | $90.09 | 2020-2025 | |
| Sequel Med Tech, LLC | $76.95 | 2025 | Twiist |
| Shire North American Group INC | $74.02 | 2019 | |
| Chiesi USA, INC. | $69.68 | 2024-2025 | Mycapssa, Myalept |
| Clarus Therapeutics INC. | $67.62 | 2021 | |
| Kyowa Kirin, INC. | $62.48 | 2023-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $52.67 | 2023-2025 | Strensiq |
| Valeritas, INC. | $51.30 | 2019 | |
| Esperion Therapeutics, INC. | $49.41 | 2020-2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $47.14 | 2022-2023 | Unithroid |
| Regeneron Healthcare Solutions, INC. | $41.48 | 2019 | |
| Opko Pharmaceuticals, LLC | $36.05 | 2022 | |
| Ucb, INC. | $33.83 | 2019 | |
| Boston Scientific Corporation | $29.51 | 2023 | |
| Madrigal Pharmaceuticals | $28.23 | 2025 | Rezdiffra |
| Ascensia Diabetes Care US INC. | $24.73 | 2023 | |
| Amryt Pharma Holdings LTD | $22.87 | 2023 | Mycapssa |
| Globus Medical, INC. | $22.24 | 2025 | Senza |
| Nevro Corp. | $21.11 | 2024 | Senza |
| Recordati_rare_diseases_inc. | $19.89 | 2020 | |
| Averitas Pharma INC. | $17.96 | 2024 | Qutenza |
| Companion Medical, INC. | $15.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.